# Herbal Botanical Products, LLC

We formulate and sell topical pain management products infused with CBD isolate, Nano CBD, and CBG.

## Elevator pitch
We formulate products infused with cannabinoid compounds including CBD, CBG, CBN, and select Terpenes from the Sativa L Cannabis plant.

- Canonical URL: https://wefunder.com/herbal.botanical.products.llc
- Entity ID: wefunder:company:86948
- Last updated: 2026-08-08T05:00:42Z
- Generated at: 2026-08-08T19:49:44Z

## Quick facts
- 💰 Proven Leadership Team with over $100 million raised over their career.
- Fast-Growing CBD Industry is experiencing Exploding Demand
- 📈 High Operating Margins and Strong Financial Leadership
- 🙌 Highly Effective and Potent Product Set
- 🤝 Key Celebrity Endorsements and Partnerships

## Active fundraises
- wefunder:fundraise:46086: 4(a)(6) successful (USD)
- wefunder:fundraise:46087: 4(a)(6) successful (USD)

## Story
Herbal Botanical Products, LLC: Fast FactsHerbal Botanical Products, LLC develops proprietary topical pain products infused with a combination of cannabinoids including CBD, CBG, CBN and select terpenes derived from the Cannabis Sativa L industrial hemp plant. Our customers use our topical pain products to help to manage a wide variety of chronic pain issues.Key HighlightsWe operate under the brand name Theá Panakeia Botanicals In Greek mythology, Panakeia was the goddess of natural remedies in Greek mythology, where she would treat people with natural potions & poultices to heal people. Because of the superior quality and effectiveness of our topical pain management products, we were selected to participate in Kevin Harrington’s Health & Wellness market campaign on Connected TV in 2020, through his company Shark Discoveries and As Seen on TV. We have also been offered the opportunity to be a Platinum Marketing Partner with The Arthritis Foundation, with access to their 600,000+ Members.Strategic PartnersKEY INDUSTRY Health and Wellness; Pain ManagementDUAL-ADDRESSABLE MARKET SIZEThe global chronic pain treatment market valued $77.8 billion in 2019, and it is expected to grow at a 6.5% CAGR during between 2020 and 2030. The CBD market is expected to reach 56.2 billion by 2028.TARGET CUSTOMERSCustomers who have chronic pain issues, including arthritis patients & physical therapy patients. Typically, these individuals are affluent, 55+, college educated and lead active lifestyles.Many CBD Products are IneffectiveStudies show that Cannabidiol (CBD) can be effective in the treatment of chronic pain, yet hundreds of CBD products on the market offer little to no efficacy for pain management.The reason for this is the lack of formulation guidelines and the proliferation of low grade product with little to no CBD concentration, which leads to ineffectiveness.It’s estimated that 95% of “ordinary” CBD (isolate) is not absorbed into the bloodstream, remaining trapped in the lymph nodes or dissolved by stomach acid, which further reduces effectiveness.* Source: National Library of Medicine, publication PMC 7558665, “Towards Better Delivery of Cannabidiol (CBD)Effective Topical CBD SolutionsHerbal Botanical Products, LLC, operating under the brand name Theá Panakeia Botanicals , provides pharmaceutical grade topical pain management products at fair prices to people dealing with chronic pain issues.We use a combination of fully water soluble, nano-sized CBD, isolate CBD, CBG, CBN, and anti inflammatory terpenes, which creates an “entourage effect” that provides anti inflammatory boosts and high quality absorption, which increases.BIOAVAILABILITY. The result is increased effectiveness of the CBD effect, which consumers have expressed is their number one buying criteria when selecting CBD infused products.The Science Behind the ProductsAll of our products are clinical grade with a focus on quality, concentration, effectiveness, and value. All products are designed to:CBD is a proven anti inflammatory agent* and acts as a neural blocker for topical management of many types of chronic pain. When our topical pain creams are applied to an affected area, the active ingredients are absorbed through the dermis by following the hair follicles into the Endo-Cannabinoid System (ECS).Available ProductsTraction & AccomplishmentsBusiness Model & Revenue StreamsREVENUE STREAMInvestment OpportunityHerbal Botanical Products, LLC is seeking $124,000 in the form of Redeemable Preferred Equity Security.T E R M SThe Company plans to issue Redeemable Preferred Equity Units at a value of $100.00 The Redeemable Units will have a mandatory redemption at the sixty-first month from issuance. The Company will also have the right to redeem the Units at any anniversary of the original issuance.The Units will have an annual cumulative redemption premium of 25%. The initial investors who invest during the "Early Bird" period (defined as the first $124,000 or 1,240 Units), will receive, in addition to the cumulative annual dividends, a special "Issuance Dividend" of another 25% dividend.If the Preferred Units remain outstanding for the full term the total return to initial investors will be $250 and subsequent Investors will receive $225 per Unit upon redemption, a 2.5X and 2.25X cash-on-cash return.The Crowd also receives Product Perks equal to 20% of the invested amount - Larger Investment = More Free Products.Company ValuationBased on the offered securities structure the Company is valued at a premoney valuation of $12.5 million, depending on the final amount of equity issued.Initial Investors DiscountInvestors in the first $124,000 of the offering receive an issuance bonus dividend accrual of 25%.Term/DurationUp to 60 monthsRedemption Premium25% cumulative annual premium based on Par Value, paid quarterly in arrearsFunding will allow us to reach +- $40 to $50 million in revenue annually, which will produce $27 to $30 million in gross profit and roughly $15 million in annual operating income. Investment Opportunity – Product PerksInvestors who participate in the General Offering will receive the following Product Perks:Why Invest?Growing MarketThe global chronic pain treatment market was valued at $77.8 billion in 2019 and is expected to grow at a 6.5% CAGR between 2020 and 2030. The market size for topical pain products is $2.5 billion and expected to grow at a 6% CAGR. Plus, the CBD market is poised to reach $56.2 billion by 2028 resulting in a total addressable market for the Company of $134.0 billion.Superior ProductsOur pharmaceutical-grade products feature a combination of fully water-soluble nano-sized CBD, isolate CBD, and terpenes for maximum effectiveness, and increased bioavailability for greater effectiveness.Outsized Gross Profit MarginsEven though our products are priced at or below market, gross margins remain at outsized levels (+- 70%) and there is pricing power for products that are of high quality and effectiveness.Recurring Revenue modelOnce customers use our pain products, almost all reorder creating a recurring revenue model which is much more valuable than a simple product sale model.Key PartnershipsWe were selected to participate in Kevin Harrington’s upcoming Health & Wellness market campaign on Connected TV. We are a marketing partner with The Villages News.com which has digital marketing assets serving The Villages in Florida, DMDatabase for email marketing addresses and we’re also establishing partnerships with The Arthritis Foundation &ForbesBooks.Forward looking projections cannot be guaranteed.Want even more details?Click the image above for our full pitch deck!

## FAQ
1. **Why is the share price so high? Share price way to high? How long you all been in business? What are your net margins? How do you all plan to scale?.You all should highly consider bringing your share price down. I've studied markets and companies with all due respect and you h...**
   - Hi Timothy, thank you for your questions. The security being offered is a redeemable preferred security. Preferred equity is priced at par value which is typically $100 each. The return is a fixed 25% per year with another 25% kicker for the initial investors. The preferred equity is superior to common equity which means you get you investment and return before the common equity (me) gets anything. Plus given the outsized returns the $100 price actually works to your advantage since the more ...

## Team
- Stephen Michael McKay (President & CEO)
- Randall Allen (Senior Vice President & COO)
- Michael Wayne Loveless (Manager)

## Q&A
- Q: Why is the share price so high? Share price way to high? How long you all been in business? What are your net margins? How do you all plan to scale?.You all should highly consider bringing your share price down. I've studied markets and companies with all due respect and you have a great product line.with respect to your share price your way too high right out of the gate. the share price way to high for the common investor and I believe will turn them off. What are your revenues to date? What is your yoy growth? Avg monthly growth? any supply chain issues..do you have a plan for that? Thanks so much for your time appreciate it..
  - A: Hi Timothy, thank you for your questions. The security being offered is a redeemable preferred security. Preferred equity is priced at par value which is typically $100 each. The return is a fixed 25% per year with another 25% kicker for the initial investors. The preferred equity is superior to common equity which means you get you investment and return before the common equity (me) gets anything. Plus given the outsized returns the $100 price actually works to your advantage since the more you invest the higher your fixed return. The answer to your other questions is in the offering document, but I'll answer them here: 1) the company was formed in January 2020. 2) Gross margins are about 70% and with the proper scale our operating margins should be in the 35% range. 3) Revenues are low currently as we launched at the onset of Covid, but sales are constant and we continue to execute on our digital marketing plan. 4) Our supply chain is probably the strongest element of the infrastructure, and I am very confident in our ability to continue to source high quality product with margins continuing at current levels and improving as volume increases. Just a final note, I would love for you to jump on board. This is my fourth and final trip around the block and all current investors have been on all prior deals, which I doubt most anyone else can't say. I have made a lot of people a lot of money in the past and I am very excited about this one and the possible outcome. If you have any other questions please let me know.